Brought to you by:
Bryan Kay
Early-bird deadline for SAVS 2026 approaches
The early-bird deadline for registration at the 2026 Southern Association for Vascular Surgery (SAVS) annual meeting in Paradise Island, the Bahamas (Jan. 21–24) falls tomorrow (Dec. 13). SAVS organizers are encouraging those planning to attend to sign up before the…
Deadline extended for SCVS Young Surgeons Program
The application deadline for the Society for Clinical Vascular Surgery (SCVS) 2026 Young Vascular Surgeons Program has been extended until midnight Eastern Time on Sunday (Dec. 14). The program will take place as part of the 2026 SCVS Annual Symposium…
Medtronic announces first commercial use of Liberant thrombectomy system
Medtronic has announced the first commercial use of its Liberant thrombectomy system, which is indicated for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems. Medtronic notes that Liberant expands the…
Philips expands commercial availability of LumiGuide imaging system
Philips has announced the expanded commercial availability of LumiGuide 3D device guidance—the much-heralded first real-time artificial intelligence (AI)-enabled light-based navigation solution for image-guided therapy—across Europe and the U.S. LumiGuide integrates with Philips’ Azurion platform, which is designed to drive procedural…
CREST-2: Landmark trial finds benefit from carotid stenting
The National Institutes of Health (NIH)-funded CREST-2 study has found that, for people with high-grade asymptomatic carotid artery stenosis who have not experienced recent stroke symptoms, a carotid artery stenting (CAS) procedure—combined with intensive medical therapy—significantly lowered stroke and death…
Chronic venous insufficiency: Appeal over ‘not-approvable’ VenoValve fails
enVVeno Medical has announced that it received an “unfavorable” decision from the Food & Drug Administration (FDA) in response to its supervisory appeal of the “not-approvable” letter it received on Aug. 19 in response to its premarket approval (PMA) application…
enVVeno receives ‘unfavorable’ appeal decision from FDA for VenoValve device
enVVeno Medical has announced that it has received an “unfavorable” decision from the Food & Drug Administration (FDA) in response to its supervisory appeal of the not-approvable letter it received on Aug. 19 in response to its premarket approval (PMA)…
Elucid launches PlaqueIQ image analysis software for carotid arteries
Elucid has announced the launch of its PlaqueIQ image analysis software for the quantification and classification of plaque morphology in the carotid arteries. According to the company, as the “first and only” computed tomography (CT)-based plaque analysis software indicated for the…
PROMISE III: Six-month data ‘reinforce’ case for TADV in no-option CLTI patients
Six-month outcomes among no-option chronic limb-threatening ischemia (CLTI) patients treated using transcatheter arterialization of the deep veins with the LimFlow system (Stryker/Inari Medical) in the PROMISE III trial showed a 81% rate of amputation-free survival. Principal investigator Daniel Clair, MD,…
One-year results from IVC stent clinical trial show positive safety and efficacy data
Twelve-month results from the clinical trial assessing a dedicated venous stent for the treatment of symptomatic inferior vena cava (IVC) obstruction with or without combined iliofemoral obstruction showed the device exceeded its performance goal for freedom from a composite of…